MX2015008010A - Compuestos radiosensabilizadores para usarse en combinacion con radiacion. - Google Patents

Compuestos radiosensabilizadores para usarse en combinacion con radiacion.

Info

Publication number
MX2015008010A
MX2015008010A MX2015008010A MX2015008010A MX2015008010A MX 2015008010 A MX2015008010 A MX 2015008010A MX 2015008010 A MX2015008010 A MX 2015008010A MX 2015008010 A MX2015008010 A MX 2015008010A MX 2015008010 A MX2015008010 A MX 2015008010A
Authority
MX
Mexico
Prior art keywords
combination
radiosensitizer compounds
radiation
radiosensitizer
disclosed
Prior art date
Application number
MX2015008010A
Other languages
English (en)
Spanish (es)
Inventor
qing-bin Lu
Original Assignee
qing-bin Lu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by qing-bin Lu filed Critical qing-bin Lu
Publication of MX2015008010A publication Critical patent/MX2015008010A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/52Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
MX2015008010A 2012-12-20 2013-12-20 Compuestos radiosensabilizadores para usarse en combinacion con radiacion. MX2015008010A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261797983P 2012-12-20 2012-12-20
PCT/CA2013/051005 WO2014094178A1 (en) 2012-12-20 2013-12-20 Radiosensitizer compounds for use in combination with radiation

Publications (1)

Publication Number Publication Date
MX2015008010A true MX2015008010A (es) 2016-04-26

Family

ID=50977492

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008010A MX2015008010A (es) 2012-12-20 2013-12-20 Compuestos radiosensabilizadores para usarse en combinacion con radiacion.

Country Status (10)

Country Link
US (1) US9655965B2 (enExample)
EP (1) EP2935215B1 (enExample)
JP (1) JP6321673B2 (enExample)
KR (1) KR102278760B1 (enExample)
CN (1) CN105164107B (enExample)
AU (1) AU2013362757B2 (enExample)
BR (1) BR112015014855A2 (enExample)
CA (1) CA2895526C (enExample)
MX (1) MX2015008010A (enExample)
WO (1) WO2014094178A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380700A (zh) * 2013-10-08 2022-04-22 卢庆彬 用于靶向化疗的非铂基抗癌化合物
EA037555B1 (ru) * 2015-04-02 2021-04-13 Проксимэйджен, Элэлси Применение 6-{4-[1-(пропан-2-ил)пиперидин-4-ил]-1,4-диазепан-1-ил}-n-(пиридин-4-ил)пиридин-2-карбоксамида для лечения раковых заболеваний цнс
CN106045932B (zh) * 2016-06-06 2018-05-15 浙江省肿瘤医院 一种具有放射增敏作用的化合物及其应用
JP6955243B2 (ja) * 2017-02-24 2021-10-27 学校法人北里研究所 ネクローシスの検出キット及びその使用
EP3804719A4 (en) * 2018-05-30 2022-03-30 Pharos Ibio Co., Ltd. Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy
WO2021224186A1 (en) * 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
CN114478524A (zh) * 2022-03-15 2022-05-13 江苏省肿瘤医院 1,8-萘啶类化合物及其应用
CN114560799A (zh) * 2022-03-15 2022-05-31 江苏省肿瘤医院 腈基取代苯基类化合物及其应用
CN120501862B (zh) * 2025-07-18 2025-10-10 四川大学华西医院 一种能够放射增敏和防护放射性损伤的双效化合物、包含其的组合物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011451B1 (enExample) * 1969-05-05 1975-05-01
CH559729A5 (enExample) * 1970-10-23 1975-03-14 Hoechst Ag
US3822261A (en) * 1972-10-30 1974-07-02 Dow Chemical Co 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines
GR72941B (enExample) * 1978-10-20 1984-01-16 Lilly Co Eli
US4210647A (en) * 1979-06-18 1980-07-01 Eli Lilly And Company Antiviral combinations
JPS597175A (ja) * 1982-07-01 1984-01-14 メルク・エンド・カムパニ−・インコ−ポレ−テツド 放射線治療用添加剤として有用な、クロロニトロアミノピラジン及びアルキルアミノピラジンのアミノとアミド誘導体
GB8722488D0 (en) * 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
ES2313714T3 (es) * 1992-06-22 2009-03-01 The Regents Of The University Of California Antagonistas de receptores de glicina y uso de los mismos.
EP0743855A1 (en) * 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
CA2397665A1 (en) * 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
ZA200708367B (en) * 2005-04-01 2009-04-29 Taiho Pharmaceutical Co Ltd Potentiator for radiation therapy comprising pyridine derivative as active ingredient
BRPI0608327A2 (pt) * 2005-04-01 2009-12-29 Taiho Pharmaceutical Co Ltd potenciador para terapia de radiação compreendendo derivado de piridina como ingrediente ativo
EP2049481A2 (en) * 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
JP2010504980A (ja) * 2006-09-28 2010-02-18 エグゼリクシス, インコーポレイテッド Jak−2モジュレーターおよび使用方法
CN101611007A (zh) * 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
MX2011004953A (es) * 2008-11-10 2011-12-14 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
WO2011026219A1 (en) 2009-09-01 2011-03-10 Lu qing-bin Combination therapy for cancer comprising a platinum -based antineoplastic agent and a biocompatible electron donor
WO2011143419A1 (en) * 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists

Also Published As

Publication number Publication date
KR102278760B1 (ko) 2021-07-20
CN105164107A (zh) 2015-12-16
CA2895526C (en) 2021-08-24
US9655965B2 (en) 2017-05-23
BR112015014855A2 (pt) 2017-07-11
CA2895526A1 (en) 2014-06-26
US20150343059A1 (en) 2015-12-03
JP6321673B2 (ja) 2018-05-09
EP2935215B1 (en) 2019-11-13
AU2013362757B2 (en) 2018-06-14
JP2016504325A (ja) 2016-02-12
EP2935215A4 (en) 2016-10-26
CN105164107B (zh) 2017-12-05
KR20150120953A (ko) 2015-10-28
EP2935215A1 (en) 2015-10-28
AU2013362757A1 (en) 2015-07-30
WO2014094178A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX2015008010A (es) Compuestos radiosensabilizadores para usarse en combinacion con radiacion.
CA2871471C (en) Dna-pk inhibitors
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
WO2012104007A3 (de) 7-azaindolderivate
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX349004B (es) Nuevos compuestos.
MD20140002A2 (ro) Indazoli
IN2012DN02081A (enExample)
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12013501600A1 (en) Novel heterocyclic derivatives
MX2014013090A (es) Derivados de pirrolotriazinona.
PH12015501609A1 (en) Phenicol antibacterials
UA112795C2 (uk) Біциклічні піразинонові похідні
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
GB201209587D0 (en) Therapeutic compounds
WO2013040227A3 (en) Therapeutic compounds
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
AU2012240222A8 (en) Methods of treating central nervous system tumors
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
PH12013500275A1 (en) Novel trpv3 modulators
MX2016008042A (es) Derivados de imidazopirazinona.